Company / Accounts Receivable
Serina Therapeutics, Inc. Accounts Receivable History
FY2018-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$57.0K
FY2023
5-year range
$4.0K / $57.0K
FY2019-FY2023
Trend
+1325.0%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Accounts Receivable changed +1325% YoY in FY2023, a notable deviation from the 4-year average annual change of +324%.
Based on SEC 10-K filings.
$57,000 in FY2023 with a 5-year CAGR of -15.3%.
Improved from $25,000 to $57,000 over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -44.1%
- 5-Year CAGR
- -15.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -15.3%, indicating a declining trend.
- In FY2023, accounts receivable increased 1325.0% year-over-year.
- Peak accounts receivable was recorded in FY2020.
- Lowest accounts receivable in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -18.20 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $57.0K | +1325.0% |
| FY2022 | $4.0K | -84.0% |
| FY2021 | $25.0K | -92.3% |
| FY2020 | $326.0K | +148.9% |
| FY2018 | $131.0K | - |
As of FY2023 · SEC 10-K Annual Filings · Updated Jun 24, 2026